Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led to massive shareholder returns. Editas Medicine (NASDAQ: EDIT) is a promising clinical-stage company that has captured Wall Street's attention at the forefront of the gene-editing revolution with a unique approach to CRISPR technologies.On the other hand, Editas faces a long road ahead before delivering its first Food and Drug Administration (FDA) approved therapy and reaching its goal of transforming into a commercially sustainable biotech. The stock, with a market capitalization of $170 million, has also been extremely volatile, down 62% over the past year despite a sharp 32% rebound in the past month as of this writing.Here's why you should proceed with caution if you're thinking about buying shares of Editas Medicine for your portfolio.Continue reading
The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led to massive shareholder returns. Editas Medicine (NASDAQ: EDIT) is a promising clinical-stage company that has captured Wall Street's attention at the forefront of the gene-editing revolution with a unique approach to CRISPR technologies.
On the other hand, Editas faces a long road ahead before delivering its first Food and Drug Administration (FDA) approved therapy and reaching its goal of transforming into a commercially sustainable biotech. The stock, with a market capitalization of $170 million, has also been extremely volatile, down 62% over the past year despite a sharp 32% rebound in the past month as of this writing.
Here's why you should proceed with caution if you're thinking about buying shares of Editas Medicine for your portfolio.
